Skip links

Shifting the limits of resuscitation with “CIRD Controlled Integrated Resuscitation Device” (CIRDinnova)

Project summary

Only 3% of the patients survive out-of-hospital resuscitation, and only 18% survive in-hospital resuscitation. In order to increase survival, a therapy was developed named CARL: Controlled Automated Reperfusion of the whoLe body. In this project, the technology is further developed from TRL 7 towards TRL 9.


Bringing the CARL therapy towards the market, resulting in improved survival rates and better quality of life for survivors after resuscitation.

More detailed information

Principal Investigator:

Dinis Dos Reis Miranda

Role Erasmus MC:



Project website:

Not available

Funding Agency:

Horizon 2020 Fast Track to Innovation Pilot